Analyst Consensus ?
ConsensusBuy13 ratings
Bullish1184.6%
Neutral215.4%
Bearish00.0%
STERIS plc · STE · FY2025 Q2 · Calendar Q4 2024
STERIS: Recurring demand supports outlook, but costs and AST weigh
STERIS's recurring consumables and services demand supports the case for continued growth, but the quarter does not remove concerns about margins, AST execution, capital equipment, and litigation.
Reported After market closeNYSEHealthcare
$21.64B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.14
Consensus $2.11
EPS surprise
+1.4%
Reported versus consensus
Reported revenue
$1.33B
Consensus $1.33B
Revenue surprise
-0.1%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-5.3%
Event window
SPY move
+0.8%
Same window
Abnormal move
-6.1%
Stock minus SPY
Volume
2.2×
Versus trailing sessions
Subsequent drift
+0.2%
Up to 20 sessions
STESPY benchmark
Ask FN2 about STE FY2025 Q2
Transcript, numbers and history already loaded
Why did STE fall 5.3% after beating EPS estimates in FY2025 Q2?What changed in STE's guidance and outlook in FY2025 Q2?Give me the bull and bear case for STE after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current quarter added a more cautious operating profile: management cited a larger-than-expected one-time Med-X equipment loss, weaker healthcare capital-equipment timing, and AST performance below double-digit growth expectations, while retaining the broader outlook.
Guidance delta
Management maintained the FY2025 outlook, while the discussion highlighted a flat EBIT margin outlook and a second-half bioprocessing recovery as important execution points.
Key takeaways
- Revenue and adjusted EPS growth showed continued operating momentum, led by healthcare consumables and services.
- Recurring demand provides support, while healthcare capital equipment and AST performance remain softer areas.
- The investment case is balanced by labor and energy cost pressure, a one-time Med-X loss, and litigation exposure.
Management priorities
- Accelerate bioprocessing growth in the second half of FY2025.
- Use recurring consumables and services to support margin expansion.
- Continue tuck-in acquisition discipline alongside share repurchases, debt reduction, and Asia Pacific capacity investment.
Follow STE with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$221.97Previous close
$245Low
$264.75Average
$275High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 20, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Buy | Maintain | Aug 7, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Aug 7, 2026 |
| Keybanc | Overweight | Overweight | Maintain | May 13, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Aug 8, 2025 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | May 16, 2025 |
| Stephens & Co. | Overweight | Overweight | Maintain | May 15, 2025 |
| Needham | Hold | Hold | Maintain | Apr 7, 2025 |
| Baird | Outperform | Outperform | Maintain | Aug 11, 2021 |
| Sidoti & Co. | Buy | Buy | Maintain | Nov 25, 2020 |
| Raymond James | Outperform | Strong Buy | Downgrade | Nov 25, 2020 |
| Griffin Securities | Hold | Buy | Downgrade | Nov 25, 2020 |
| Bank of America | Buy | Buy | Maintain | Nov 25, 2020 |
| B of A Securities | Buy | Buy | Maintain | Mar 15, 2013 |
Named analyst price targets
Upside is calculated against the persisted previous close $221.97. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Patrick Wood | $275 | $218.4 | +23.9% | Jul 28, 2026 |
| Piper Sandler | Jason Bednar | $270 | $216.18 | +21.6% | May 21, 2026 |
| KeyBanc | Brett Fishbin | $269 | $210.85 | +21.2% | May 13, 2026 |
| Piper Sandler | Jason Bednar | $260 | $221.15 | +17.1% | Oct 24, 2024 |
| KeyBanc | Brett Fishbin | $265 | $241.1 | +19.4% | Sep 3, 2024 |
| Piper Sandler | Jason Bednar | $225 | $225.94 | +1.4% | May 10, 2024 |
| Wolfe Research | Mike Polark | $245 | $216.65 | +10.4% | Apr 4, 2024 |
Track every rating change on STE the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationSTERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
Historical context
All STE earningsLatest beats and misses
Who reports nextBeat on EPS
Missed on EPS
Get the STE recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-10T18:38:36.707185+00:00
- Polygon adjusted daily market bars · 2026-10-20T08:10:41.993222+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-20T08:10:41.990532+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-20. For educational purposes only; not investment advice.